{"DataElement":{"publicId":"6299938","version":"1","preferredName":"Acute Myeloid Leukemia Disease Response Status","preferredDefinition":"Text term to describe the acute myeloid leukemia disease response status based on morphological evaluation.","longName":"AML_DZ_RESP_STS","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"6299936","version":"1","preferredName":"Acute Myeloid Leukemia Disease Response Evaluation","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification)._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"2320063v1.0:6118200v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2320063","version":"1","preferredName":"Acute Myeloid Leukemia","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","longName":"C3171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-037A-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6118200","version":"1","preferredName":"Disease Response Evaluation","preferredDefinition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"C50995:C25214","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66EE8121-3F37-01B4-E053-F662850AB193","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Princess Margaret Cancer Centre, Toronto, ON","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CDF8C78-AD7B-5EAA-E053-F662850A4FBC","latestVersionIndicator":"Yes","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"MAESKEB","dateModified":"2018-07-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6297963","version":"1","preferredName":"Acute Myeloid Leukemia Response Status","preferredDefinition":"A condition or state at a particular time.","longName":"AML_RESP_STS","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Complete Remission (CR)","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3854972","version":"1","preferredName":"Complete Remission","longName":"3854972","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86FD-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CB78336-0470-6070-E053-F662850A7FD3","beginDate":"2018-05-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-21","modifiedBy":"ONEDATA","dateModified":"2018-05-21","deletedIndicator":"No"},{"value":"Relapse","valueDescription":"Relapse","ValueMeaning":{"publicId":"5035791","version":"1","preferredName":"Relapse","longName":"5035791","preferredDefinition":"The return of signs and symptoms of cancer after a period of improvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relapse","conceptCode":"C0699753","definition":"The return of signs and symptoms of cancer after a period of improvement.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"223EE1E8-286D-61CF-E050-BB89AD436EF1","latestVersionIndicator":"Yes","beginDate":"2015-10-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CBA8BB7-CF72-7C6F-E053-F662850ABB92","beginDate":"2018-05-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-21","modifiedBy":"ONEDATA","dateModified":"2018-05-21","deletedIndicator":"No"},{"value":"Partial Remission (PR)","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"3951935","version":"1","preferredName":"Partial Remission","longName":"3951935","preferredDefinition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB155E17-C5B7-CEC3-E040-BB89AD4342C2","latestVersionIndicator":"Yes","beginDate":"2013-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CBA8BB7-CF7C-7C6F-E053-F662850ABB92","beginDate":"2018-05-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-21","modifiedBy":"ONEDATA","dateModified":"2018-05-21","deletedIndicator":"No"},{"value":"Complete remission with Incomplete Platelet Recovery (CRp)","valueDescription":"Complete Remission With Incomplete Platelet Recovery","ValueMeaning":{"publicId":"3855478","version":"1","preferredName":"Complete Remission With Incomplete Platelet Recovery","longName":"3855478","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.: Used to indicate the presence of something or someone.: Not whole; lacking some necessary part or detail; unfinished.: An irregular, disc-shaped element in the blood that assists in blood clotting. Platelets are not blood cells, they are fragments of large bone marrow cells called megakaryocytes: A getting back or regaining.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Incomplete","conceptCode":"C49160","definition":"Not whole; lacking some necessary part or detail; unfinished.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Platelet","conceptCode":"C12520","definition":"An irregular, disc-shaped element in the blood that assists in blood clotting. Platelets are not blood cells, they are fragments of large bone marrow cells called megakaryocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recovery","conceptCode":"C70827","definition":"A getting back or regaining.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F05B4C-B026-99BA-E040-BB89AD4372F4","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CBA8BB7-CFBE-7C6F-E053-F662850ABB92","beginDate":"2018-05-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-21","modifiedBy":"ONEDATA","dateModified":"2018-05-21","deletedIndicator":"No"},{"value":"Complete Remission with Incomplete Hematological Recovery (CRi)","valueDescription":"Complete Remission with Incomplete Hematological Recovery","ValueMeaning":{"publicId":"6301226","version":"1","preferredName":"Complete Remission with Incomplete Hematological Recovery","longName":"6301226","preferredDefinition":"The disappearance of all signs of cancer in response to treatment with residual neutropenia (less than 1,000 per microliter), with or without complete platelet recovery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission with Incomplete Hematological Recovery","conceptCode":"C150587","definition":"The disappearance of all signs of leukemia in response to treatment with residual neutropenia (less than 1,000 per microliter), with or without complete platelet recovery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CE9F570-777C-3409-E053-F662850A610A","latestVersionIndicator":"Yes","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CE9F570-7795-3409-E053-F662850A610A","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","deletedIndicator":"No"},{"value":"Morphologic leukemia-free state (MLFS)","valueDescription":"Morphologic Leukemia - Free State","ValueMeaning":{"publicId":"2581112","version":"1","preferredName":"Morphologic Leukemia - Free State","longName":"2581112","preferredDefinition":"The disappearance of all cells with morphologic characteristics of leukemia, accompanied by bone marrow recovery, in response to treatment. Hematologic recovery is not required. Leukemia free state can be a hypocellular marrow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Leukemia-Free State","conceptCode":"C123597","definition":"The disappearance of all cells with morphologic characteristics of leukemia, accompanied by bone marrow recovery, in response to treatment. Hematologic recovery is not required. Leukemia free state can be a hypocellular marrow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-09E5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"COOPERM","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CE9F570-77AB-3409-E053-F662850A610A","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","deletedIndicator":"No"},{"value":"Refractory Disease","valueDescription":"Refractory Disease","ValueMeaning":{"publicId":"4571271","version":"1","preferredName":"Refractory Disease","longName":"4571271","preferredDefinition":"A disease that resists treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Disease","conceptCode":"C39752","definition":"A disease that resists treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"06FECA4E-7E2B-9714-E050-BB89AD432ED0","latestVersionIndicator":"Yes","beginDate":"2014-11-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-11-03","modifiedBy":"KUMMEROA","dateModified":"2023-03-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"73F412E4-DBAE-2654-E053-F662850A1803","beginDate":"2018-08-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-21","modifiedBy":"ONEDATA","dateModified":"2018-08-21","deletedIndicator":"No"},{"value":"Molecular relapse (after CRMRD-)","valueDescription":"Molecular Relapse Post Minimal Residual Disease","ValueMeaning":{"publicId":"6690867","version":"1","preferredName":"Molecular Relapse Post Minimal Residual Disease","longName":"6690867","preferredDefinition":"Relating to or produced by or consisting of molecules.: The return of signs and symptoms of cancer after a period of improvement.: Happening at a time subsequent to a reference time; later in time or order.: Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Molecular","conceptCode":"C25574","definition":"Relating to or produced by or consisting of molecules.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Relapse","conceptCode":"C0699753","definition":"The return of signs and symptoms of cancer after a period of improvement.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"2"},{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Measurable Residual Disease","conceptCode":"C3896","definition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8657A0AD-2355-0C75-E053-F662850A17D9","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8657A0AD-236E-0C75-E053-F662850A17D9","beginDate":"2019-04-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","deletedIndicator":"No"},{"value":"Hematologic relapse (after CRMRD-, CR, CRi)","valueDescription":"Hematologic Relapse Post Complete Remission Minimal Residual Disease Complete Remission with Incomplete Hematological Recovery","ValueMeaning":{"publicId":"6690868","version":"1","preferredName":"Hematologic Relapse Post Complete Remission Minimal Residual Disease Complete Remission with Incomplete Hematological Recovery","longName":"6690868","preferredDefinition":"Pertaining to or related to the blood and blood-forming organs.: The return of signs and symptoms of cancer after a period of improvement.: Happening at a time subsequent to a reference time; later in time or order.: The disappearance of all signs of cancer in response to treatment.: Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.: The disappearance of all signs of cancer in response to treatment with residual neutropenia (less than 1,000 per microliter), with or without complete platelet recovery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic","conceptCode":"C62780","definition":"Pertaining to or related to the blood and blood-forming organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Relapse","conceptCode":"C0699753","definition":"The return of signs and symptoms of cancer after a period of improvement.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"4"},{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Measurable Residual Disease","conceptCode":"C3896","definition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission with Incomplete Hematological Recovery","conceptCode":"C150587","definition":"The disappearance of all signs of leukemia in response to treatment with residual neutropenia (less than 1,000 per microliter), with or without complete platelet recovery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8657A0AD-237F-0C75-E053-F662850A17D9","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8657A0AD-2398-0C75-E053-F662850A17D9","beginDate":"2019-04-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","deletedIndicator":"No"},{"value":"Death due to indeterminate cause","valueDescription":"Death by Undetermined Cause","ValueMeaning":{"publicId":"6690959","version":"1","preferredName":"Death by Undetermined Cause","longName":"6690959v1.00","preferredDefinition":"Death resulting from an unknown cause.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Death by Undetermined Cause","conceptCode":"C82466","definition":"Death resulting from an unknown cause.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8659914D-F08E-7604-E053-F662850ABF57","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-12","modifiedBy":"KUMMEROA","dateModified":"2023-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"869184CB-657E-7DB9-E053-F662850AA846","beginDate":"2019-04-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-15","modifiedBy":"ONEDATA","dateModified":"2019-04-15","deletedIndicator":"No"},{"value":"Death in aplasia","valueDescription":"Death in aplasia","ValueMeaning":{"publicId":"6690863","version":"1","preferredName":"Death in aplasia","longName":"6690863","preferredDefinition":"Death in aplasia","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86575C12-456A-1396-E053-F662850A0413","latestVersionIndicator":"Yes","beginDate":"2019-04-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86575C12-4583-1396-E053-F662850A0413","beginDate":"2019-04-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","deletedIndicator":"No"},{"value":"Primary refractory disease","valueDescription":"Primary Refractory Disease","ValueMeaning":{"publicId":"6617853","version":"1","preferredName":"Primary Refractory Disease","longName":"6617853","preferredDefinition":"Occurring first in time or sequence; original; of greatest rank or importance or value.: A disease that resists treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary","conceptCode":"C25251","definition":"Occurring first in time or sequence; original; of greatest rank or importance or value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Refractory Disease","conceptCode":"C39752","definition":"A disease that resists treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"800DEA32-E11B-5B5A-E053-F662850AA5D1","latestVersionIndicator":"Yes","beginDate":"2019-01-22","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-22","modifiedBy":"ONEDATA","dateModified":"2019-01-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86575C12-4597-1396-E053-F662850A0413","beginDate":"2019-04-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-12","modifiedBy":"ONEDATA","dateModified":"2019-04-12","deletedIndicator":"No"},{"value":"Clinical Benefit","valueDescription":"Clinical Benefit","ValueMeaning":{"publicId":"6384034","version":"1","preferredName":"Clinical Benefit","longName":"6384034","preferredDefinition":"An effect of a therapeutic intervention that prolongs life, improves function, and/or improves the way a subject feels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Benefit","conceptCode":"C142422","definition":"An effect of a therapeutic intervention that prolongs life, improves function, and/or improves the way a subject feels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C6BAFD-61E4-3006-E053-F662850A9BF1","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87706CAE-9B43-4FBC-E053-F662850AA9BE","beginDate":"2019-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Hematological Improvement","valueDescription":"Hematologic Improvement","ValueMeaning":{"publicId":"3855533","version":"1","preferredName":"Hematologic Improvement","longName":"3855533","preferredDefinition":"Pertaining to or related to the blood and blood-forming organs.: A condition superior to an earlier condition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic","conceptCode":"C62780","definition":"Pertaining to or related to the blood and blood-forming organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Improvement","conceptCode":"C94226","definition":"A condition superior to an earlier condition.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F3DD72-55D7-9112-E040-BB89AD436F6A","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8770886E-E7CE-4FBE-E053-F662850ABEF8","beginDate":"2019-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Marrow Response","valueDescription":"Bone Marrow Remission","ValueMeaning":{"publicId":"6732990","version":"1","preferredName":"Bone Marrow Remission","longName":"6732990","preferredDefinition":"The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.: An abatement in intensity or degree (as in the manifestations of a disease).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone Marrow","conceptCode":"C12431","definition":"The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Remission","conceptCode":"C18246","definition":"An abatement in intensity or degree (as in the manifestations of a disease).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8770886E-E7DC-4FBE-E053-F662850ABEF8","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8770886E-E7F7-4FBE-E053-F662850ABEF8","beginDate":"2019-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Progressive Disease","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"3284666","version":"1","preferredName":"Progressive Disease","longName":"3284666v1.00","preferredDefinition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD9FC7D6-531D-BE97-E040-BB89AD437875","latestVersionIndicator":"Yes","beginDate":"2011-09-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-23","modifiedBy":"MMADDINENI","dateModified":"2024-02-22","changeDescription":null,"administrativeNotes":"2023.5.17 Alt VM added per ticket request CADSR0002435. ak \r\n2023.3.15 Per LS at COG Protocol defined progressive disease (should have been added as a VM Alt Name for PV 3284666). ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"875AC308-8350-7431-E053-F662850A40C0","beginDate":"2019-04-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","deletedIndicator":"No"},{"value":"Stable Disease","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2982985","version":"1","preferredName":"Stable Disease","longName":"2982985","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-0176-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"875AC308-835B-7431-E053-F662850A40C0","beginDate":"2019-04-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","deletedIndicator":"No"},{"value":"Partial Response","valueDescription":"Partial Response","ValueMeaning":{"publicId":"2559721","version":"1","preferredName":"Partial Response","longName":"2559721","preferredDefinition":"A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Response","conceptCode":"C18212","definition":"A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B656-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SOKKERL","dateModified":"2023-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"875AC308-8365-7431-E053-F662850A40C0","beginDate":"2019-04-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","deletedIndicator":"No"},{"value":"Complete Response","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3854972","version":"1","preferredName":"Complete Remission","longName":"3854972","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86FD-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"875AC308-8371-7431-E053-F662850A40C0","beginDate":"2019-04-25","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-25","modifiedBy":"ONEDATA","dateModified":"2019-04-25","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"6424136","version":"1","preferredName":"Other","longName":"6424136","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"753441A1-068C-5A23-E053-F662850A6B7A","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-02","changeDescription":null,"administrativeNotes":"2023.2.2 Alt VM added per ticket request CADSR0002006. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97531D5B-8402-2F4B-E053-F662850A8809","beginDate":"2019-11-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-14","modifiedBy":"ONEDATA","dateModified":"2019-11-14","deletedIndicator":"No"},{"value":"CR with Partial Hematologic Recovery(CRh)","valueDescription":"CR with partial hematologic recovery","ValueMeaning":{"publicId":"7058733","version":"1","preferredName":"CR with partial hematologic recovery","longName":"7058733","preferredDefinition":"CR with partial hematologic recovery","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97531D5B-840C-2F4B-E053-F662850A8809","latestVersionIndicator":"Yes","beginDate":"2019-11-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-14","modifiedBy":"ONEDATA","dateModified":"2019-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97451AE9-FBB6-17B4-E053-F662850AB615","beginDate":"2019-11-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-14","modifiedBy":"ONEDATA","dateModified":"2019-11-14","deletedIndicator":"No"},{"value":"CR without MRD (CRMRD)","valueDescription":"Complete Remission Without Minimal Residual Disease","ValueMeaning":{"publicId":"3855479","version":"1","preferredName":"Complete Remission Without Minimal Residual Disease","longName":"3855479","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.: Used to indicate the absence or lack of something or someone. (from Merriam-Webster OnLine): remainder of a tumor or a neoplasm/cancer after primary, potentially curative therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Measurable Residual Disease","conceptCode":"C3896","definition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F05B4C-B061-99BA-E040-BB89AD4372F4","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97451AE9-FBFB-17B4-E053-F662850AB615","beginDate":"2019-04-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-14","modifiedBy":"ONEDATA","dateModified":"2019-11-14","deletedIndicator":"No"},{"value":"Hematologic Response (HR)","valueDescription":"Hematologic Response","ValueMeaning":{"publicId":"6618816","version":"1","preferredName":"Hematologic Response","longName":"6618816","preferredDefinition":"An evaluation of the hematologic response of the disease to the therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic Response","conceptCode":"C123622","definition":"An evaluation of the hematologic response of the disease to the therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"804A1D9D-3E7E-3C2A-E053-F662850A9CA8","latestVersionIndicator":"Yes","beginDate":"2019-01-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-25","modifiedBy":"ONEDATA","dateModified":"2019-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"975045B7-7C56-117E-E053-F662850A06CC","beginDate":"2019-11-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-11-14","modifiedBy":"ONEDATA","dateModified":"2019-11-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404650","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-057F-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Princess Margaret Cancer Centre, Toronto, ON","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CB78336-045C-6070-E053-F662850A7FD3","latestVersionIndicator":"Yes","beginDate":"2018-05-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-21","modifiedBy":"SOKKERL","dateModified":"2019-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"Theradex","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"Acute Myeloid Leukemia respon","type":"Preferred Question Text","description":"Acute Myeloid Leukemia response","url":null,"context":"NCIP"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Response Assessment","url":null,"context":"Theradex"},{"name":"Princess Marg 1","type":"Alternate Question Text","description":"AML response","url":null,"context":"NCIP"}],"origin":"Princess Margaret Cancer Centre, Toronto, ON","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CDF575C-69CF-5EA2-E053-F662850A9813","latestVersionIndicator":"Yes","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"SOKKERL","dateModified":"2019-11-15","changeDescription":"Acute Myeloid Leukemia response","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}